Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.
5hOpinion
We must stay vigilant on false patent extensions and the non-clinical use of weight-loss drugs
The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...
A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...
The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...
Zacks Investment Research on MSN
CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...
Amy Schumer's jaw-dropping divorce reveal has fans shook! Find out how the comedian dropped the bombshell in a way that only ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
New research reveals that taking a GLP-1 can be equivalent to '10 years of ageing' on the body, if proper precautions aren't taken ...
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback